AlphAIAlphAI — Financial news for AI agents
BenzingaOCT 203 min read$PHAT

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 - Phathom Pharmaceuticals (NASDAQ:PHAT)

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT

Original reporting
Benzinga · Globe Newswire
Published Oct 20, 2025, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2025, 1:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PHAT
Bullish
medium confidence
Mentioned
$PHAT
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$PHATBullishMed
01

Why it matters

The upcoming financial results are highly anticipated by investors and could serve as a catalyst for stock movement.

02

Market read

The event is highly relevant for investors holding or considering trading PHAT stock, especially in the short term.

03

What to watch

Potential regulatory issues or unforeseen adverse developments could negatively impact the stock regardless of earnings.

Timing: High; the event is scheduled for October 30, 2025, and traders should prepare accordingly.

Background

Phathom Pharmaceuticals specializes in developing treatments within the life sciences sector, with a focus on gastrointestinal diseases.

Company-level read

Ticker impact

$PHATBullishMedium confidence
Context

The upcoming financial results and business update from Phathom Pharmaceuticals could influence investor sentiment and stock price movements.

Expected impact

Potential short-term increase in stock price if results surpass expectations; downside risk if results are below expectations.

Evidence & confidence

Market reactions to earnings reports are historically significant but depend on actual results versus forecasts. The positive sentiment score suggests market anticipation of favorable results, but uncertainties remain.

Market effects

Sector

Positive earnings could bolster confidence in the biotech sector, especially within life sciences.

Regional

Limited; the impact is primarily localized to the company's stock and sector.

Global

Minimal; the event is specific to Phathom Pharmaceuticals and does not have immediate global market implications.

Counterpoint

What could challenge this read

Results may fall short of expectations, leading to a sell-off and increased volatility.

Key entities

  • Company
    Phathom Pharmaceuticals

    A biotechnology company focused on gastrointestinal treatments.

Read at source← All news

Related articles

SEP 29
$PHATMedAI 8/10

Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN…

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 29, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of

SEC EDGAR 8-K2 min
JUL 30
$PHATMed

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update • ~1.7 million total VOQUEZNA ® prescriptions filled to date • Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 • Q2 operatin

SEC EDGAR 8-K7 min
SEP 29
$LMTMedAI 8/10

Lockheed Martin (LMT) Secures $298 Million in New Defense Contra

Lockheed Martin (LMT) announced $298M in contract modifications for U.S. Navy and Japan's defense systems. The company offers a 2.63% dividend yield with a 50% payout ratio and 5.4% 3-year growth. Its GF Value suggests a 9.4% undervaluation. LMT has a GF Score of 89/100, with strong profitability and valuation metrics. Institutional guru ownership is robust, but insider activity shows net selling.

gurufocus.com2 min
SEP 29
$LMTMedAI 9/10

Lockheed Martin (LMT) Secures $245M Contract Modification to Exp

Lockheed Martin (LMT) received a $245M contract modification to expand production of F/A-18E/F Infrared Search and Track Block II systems for the U.S. Navy and Royal Australian Air Force. The company offers a 2.63% dividend yield, a 50% payout ratio, and a 3-year dividend growth rate of 5.4%. LMT's stock is trading 9.4% below its GF Value™ of $565.64, with a GF Score™ of 89/100. Institutional investors show mixed sentiment, while insiders have sold $4.0M in shares over the past year.

gurufocus.com2 min
SEP 29
$GMEMed

GameStop: Ryan Cohen reports 8.8% ownership stake

Ryan Cohen reported an 8.8% ownership stake in GameStop (GME), totaling 44,683,306 shares. He owns 40,948,522 shares directly, valued at $185,549,462, and 3,734,784 warrants received as a dividend. Cohen has sole voting and dispositive power over these shares, with no transactions since his last filing.

stocktitan.net1 min